Antiepidermal Growth Factor Receptor Monoclonal Antibodies: Applications in Colorectal Cancer

Table 6

Trials using anti-EGFR mAbs plus bevacizumab in chemotherapy naïve mCRC selected by KRAS.

Trial (author)	Phase	KRAS	Protocol	Number enrolled	Results		HR (95% CI)	𝑃 value
					PFS	OS
— (Tol et al.) [27]	III	WT	Capecitabine + oxaliplatin + bevacizumab + cetuximab	158	10.5 mos.	21.8 mos.	PFS: NR	0.3
			Capecitabine + oxaliplatin + bevacizumab	156	10.6 mos.	22.4 mos.	OS: NR	0.64
		MUT	Capecitabine + oxaliplatin + bevacizumab + cetuximab	98	8.1 mos.	17.2 mos.	PFS: NR	0.003
			Capecitabine + oxaliplatin + bevacizumab	108	12.5 mos.	24.9 mos.	OS: NR	0.03
PACCE (Hecht et al.) [28]	III	WT	FOLFOX + panitumumab + bevacizumab	201	9.8 mos.	20.7 mos.	PFS: 1.36 (1.04–1.77)	NR
			FOLFOX + bevacizumab	203	11.5 mos.	24.5 mos.	OS: 1.89 (1.30–2.75)	0.045
		MUT	FOLFOX + panitumumab + bevacizumab	135	10.4 mos.	19.3 mos.	PFS: 1.25 (0.91–1.71)	NR
			FOLFOX + bevacizumab	125	11.0 mos.	19.3 mos.	OS: 1.02 (0.67–1.54)	NR
— (Saltz et al.) [29]	III	WT	mFOLFOX + bevacizumab	49	10.9 mos.	18.8 mos.	PFS: NR	0.99
			FOLF + cetuximab + bevacizumab	46	8.8 mos.	21.5 mos.	OS: NR	0.96
		MUT	mFOLFOX + bevacizumab	36	12.1 mos.	22.4 mos.	PFS: NR	<0.01
			FOLF + cetuximab + bevacizumab	33	8.0 mos.	20.3 mos.	OS: NR	0.11

WT: wild type, MUT: mutated, PFS: progression free survival, OS: overall survival, and NR: not reported.